| Drug | Total patent applications | # Patents Issued | % Filed after FDA approval | Duration of patent protection | Patents filed in U.S. vs. Europe | Patents filed in U.S. vs. Japan | % Price increase 2014-2019 |
>10% Medicare annual price increase |
>5% Medicaid annual price increase |
Top 15 Medicare total spending (rank) | Medicare spending per beneficiary | On U.S. market since | Generic / biosimilar approved by FDA (year) | Generic / biosimilar on the U.S. market since (year) | Company | Condition(s) Treated | Drug Type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Humira | 257 | 130 | 90% | 39 | 3.3x | 4.1x | 69% | ✔ 17% | ✔ 16% | ✔ 6 | $42,533 | 2002 | ✔ 2016 | - | AbbVie | Arthritis | Biologic |
| Eliquis | 49 | 31 | 37% | 33.8 | 2.7x | 3.1x | 58% | ✔ 18% | ✔ 8% | ✔ 1 | $3,031 | 2012 | - | - | Pfizer/BMS | Stroke/Embolism | Small Molecule |
| Keytruda | 129 | 86 | 50% | 34.6 | 1.0x | 1.2x | 147% | ✔ 23% | - | - | $51,032 | 2014 | - | - | Merck | Cancer | Biologic |
| Revlimid | 196 | 109 | 74% | 40.4 | 2.6x | 2.6x | 34% | ✔ 14% | ✔ 9% | ✔ 2 | $103,028 | 2005 | - | - | BMS/Celgene | Multiple Myeloma | Small Molecule |
| Imbruvica | 165 | 88 | 55% | 29.2 | 3.6x | 3.9x | 42% | ✔ 19% | - | ✔ 9 | $85,128 | 2013 | - | - | AbbVie | Cancer | Small Molecule |
| Opodivo | 84 | 44 | 70% | 35.1 | 2.2x | 2.0x | 167% | ✔ 19% | ✔ 26% | - | $57,446 | 2014 | - | - | BMS | Cancer | Biologic |
| Eylea | 89 | 58 | 53% | 39.7 | 3.2x | 4.9x | 16% | - | - | - | $9,602 | 2011 | - | - | Bayer/Regeneron | Macular Degeneration | Biologic |
| Avastin | 222 | 75 | 80% | 41.6 | 2.4x | 2.1x | 21% | - | - | - | $29,687 | 2004 | ✔ 2017 | ✔ 2019 | Roche | Cancer | Biologic |
| Enbrel | 68 | 39 | 76% | 47.5 | 2.1x | 2.6x | 84% | ✔ 17% | ✔ 14% | - | $39,566 | 1998 | ✔ 2016 | - | Amgen | Arthritis | Biologic |
| Xarelto | 51 | 32 | 41% | 33.5 | 1.5x | 1.6x | 71% | ✔ 18% | ✔ 9% | ✔ 4 | $3,197 | 2011 | - | - | Johnson&Johnson | Blood Clots | Small Molecule |
| Average | 131 | 69.2 | 63% | 37.5 | 2.5x | 2.8x | 71% | $42,425 | 2008.4 |
Numbers in pink font indicate above the average for the 10 drugs
- Patent data as of August 2020
- Data on pricing changes from 2014-19 were obtained from IQVIA monthly NSP prices during that period. These represent total spending on prescription medicines from wholesaler transactions and include all on-invoice discounts, but no off-invoice discounts or rebates
- Data on prices and spending for Medicare and Medicaid were obtained from the CMS ‘Drug Spending Database’ and reflect data from 2014-2018
- Medicare price increases are based on average annual changes in the price per beneficiary over the period 2014-2018 and spending per beneficiary is for 2018
- Medicaid price increases are based on average changes in the price per claim over the period 2014-2018
- Humira and Humira Pen are combined and reflect the total for Medicare and Medicaid spending rank; annual price increases reflect the average of the two product sub-types